Pier Luigi Zinzani
皮尔·路易吉·津扎尼
MD, PhD
Professor of Hematology and Director of Lymphoma Unit血液学教授兼淋巴瘤科主任
👥Biography 个人简介
Professor Pier Luigi Zinzani is Italy's leading lymphoma physician and one of Europe's most prolific clinical investigators in B-cell malignancies. He has been a primary investigator in numerous pivotal trials across indolent B-cell lymphomas, including studies of epcoritamab in follicular lymphoma, umbralisib in marginal zone lymphoma, and lenalidomide-rituximab combinations. His group at Bologna has contributed heavily to the evidence base for MALT lymphoma management and he has authored multiple Italian and European treatment guidelines. Zinzani serves on the EHA Scientific Committee and chairs the Italian Lymphoma Foundation (FIL) clinical trials committee.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Epcoritamab in Follicular Lymphoma
Led key European cohorts of EPCORE NHL-2 evaluating epcoritamab (CD3×CD20 bispecific) in relapsed follicular lymphoma, demonstrating deep and durable responses including complete remissions in heavily pretreated patients.
Umbralisib in Marginal Zone Lymphoma
Principal investigator for the UNITY-NHL trial in marginal zone lymphoma, which supported FDA approval of umbralisib as the first PI3Kδ/CK1ε inhibitor for relapsed MZL, providing an important new option for this orphan indication.
MALT Lymphoma Management Guidelines
Co-authored the Italian and European evidence-based guidelines for MALT lymphoma management, integrating H. pylori eradication, radiation, and systemic therapy based on site, stage, and molecular features including API2-MALT1 fusion status.
Representative Works 代表性著作
Epcoritamab in relapsed or refractory follicular lymphoma: results from the EPCORE NHL-2 trial
Journal of Clinical Oncology (2023)
Phase I/II data demonstrating high response rates of epcoritamab in r/r follicular lymphoma with manageable cytokine release syndrome.
Umbralisib plus ublituximab (U2) in patients with relapsed or refractory marginal zone lymphoma: UNITY-NHL trial
Blood (2022)
Phase IIb trial supporting FDA approval of umbralisib in relapsed/refractory marginal zone lymphoma.
Management of MALT lymphoma: an evidence-based approach from the Italian Lymphoma Foundation
Haematologica (2020)
Comprehensive evidence-based guidelines integrating site-specific management strategies for gastric, pulmonary, and ocular adnexal MALT lymphoma.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-20 | All information from publicly available academic sources
Related Experts 相关专家
Hope S. Rugo
University of California, San Francisco (UCSF)
Maryam B. Lustberg
Yale School of Medicine / Yale Cancer Center
Sara M. Tolaney
Dana-Farber Cancer Institute / Harvard Medical School
Carlos H. Barrios
PUCRS (Pontifical Catholic University of Rio Grande do Sul) / Hospital São Lucas, Porto Alegre, Brazil
关注 皮尔·路易吉·津扎尼 的研究动态
Follow Pier Luigi Zinzani's research updates
留下邮箱，当我们发布与 Pier Luigi Zinzani（IRCCS Azienda Ospedaliero-Universitaria di Bologna）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment